Bluebird Bio Inc (BLUE) Gross Profit Margin starting from the first quarter 2025 to first quarter 2024, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Bluebird Bio Inc   (NASDAQ: BLUE)


Bluebird Bio Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BLUE Gross Profit Margin (Mar 31 2025)
Q1 		(Dec 31 2024)
Q4 		(Sep 30 2024)
Q3 		(Jun 30 2024)
Q2 		(Mar 31 2024)
Q1
Y / Y Revenue Change 108.43 %
Seq. Revenue Change 0.5 %
Revenue In Millions $38.71
Gross Profit Margin 68.39 %
Gross Profit Margin Total Ranking # 1098
Gross Profit In Millions $26.48
Y / Y Gross Profit Change -
Seq. Gross Profit Change 68.29 %


Commenting First Quarter 2025 Gross Profit Margin
Bluebird Bio Inc Gross Profit grew by 68.29 % in Q1 sequentially to 26 millions, while Revenue increased by 0.5 %, this led to improvement in the company's Gross Profit Margin to 68.39 %, Gross Profit Margin remained below Bluebird Bio Inc average.


Observing first quarter 2025 results within Biotechnology & Pharmaceuticals industry 21 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1098, from total ranking in the previous quarter at 2287.
Learn about Gross Margin
BLUE's Gross Profit Margin first quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 22
Healthcare Sector # 196
Overall # 1086

Gross Profit Margin Statistics
High Average Low
99.83 % 78.04 % 11.6 %
(Dec 31 2017)   (Sep 30 2023)


BLUE Gross Income Trends • More of BLUE's Profitabilty Ratios • BLUE Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
BLUE's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
BLUE's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for BLUE's Competitors
Gross Profit Margin Profit Margin for Bluebird Bio Inc 's Suppliers
Gross Profit Margin Profit Margin for BLUE's Customers

You may also want to know
BLUE's Annual Growth Rates BLUE's Profitability Ratios BLUE's Asset Turnover Ratio BLUE's Dividend Growth
BLUE's Roe BLUE's Valuation Ratios BLUE's Financial Strength Ratios BLUE's Gross Profit Growth
BLUE's Roa BLUE's Inventory Turnover Ratio BLUE's Growth Rates BLUE's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginMar 31 2025 MRQ Gross ProfitMar 31 2025 MRQ Revenue
Immunitybio inc   99.65 %$ 16.459  Millions$ 16.517  Millions
Agenus Inc  99.43 %$ 23.929  Millions$ 24.066  Millions
Immunocore Holdings Plc  99.11 %$ 93.050  Millions$ 93.881  Millions
Humacyte Inc   99.05 %$ 15.300  Millions$ 15.447  Millions
Neurocrine Biosciences Inc   98.39 %$ 563.400  Millions$ 572.600  Millions
Novavax inc   97.88 %$ 652.540  Millions$ 666.655  Millions
Lineage Cell Therapeutics Inc   97.60 %$ 1.466  Millions$ 1.502  Millions
Invivyd Inc   97.29 %$ 10.998  Millions$ 11.304  Millions
Biocryst Pharmaceuticals Inc   96.86 %$ 140.966  Millions$ 145.534  Millions
Exelixis Inc   96.55 %$ 536.275  Millions$ 555.447  Millions
Dbv Technologies S a   94.12 %$ 0.753  Millions$ 0.800  Millions
Tarsus Pharmaceuticals Inc   93.35 %$ 73.124  Millions$ 78.335  Millions
Adaptimmune Therapeutics Plc  87.93 %$ 6.406  Millions$ 7.285  Millions
X4 Pharmaceuticals Inc  83.63 %$ 24.091  Millions$ 28.807  Millions
Ginkgo Bioworks Holdings Inc   83.53 %$ 40.361  Millions$ 48.318  Millions
Halozyme Therapeutics Inc   81.73 %$ 216.458  Millions$ 264.861  Millions
Zeo Scientifix Inc   77.72 %$ 0.893  Millions$ 1.149  Millions
Gilead Sciences Inc   76.90 %$ 5,127.000  Millions$ 6,667.000  Millions
Biogen Inc   74.11 %$ 1,801.700  Millions$ 2,431.000  Millions
Scilex Holding Company  72.34 %$ 3.620  Millions$ 5.004  Millions
Vericel Corporation  68.96 %$ 36.273  Millions$ 52.598  Millions
Bluebird Bio Inc   68.39 %$ 26.475  Millions$ 38.712  Millions
Bio techne Corp  67.99 %$ 214.556  Millions$ 315.556  Millions
Dyadic International Inc   67.86 %$ 0.267  Millions$ 0.394  Millions
Adaptive Biotechnologies Corporation  67.62 %$ 35.464  Millions$ 52.443  Millions
Coherus Oncology inc   65.09 %$ 4.946  Millions$ 7.599  Millions
Xtant Medical Holdings Inc   62.78 %$ 20.243  Millions$ 32.243  Millions
Creative Medical Technology Holdings Inc   60.00 %$ 0.002  Millions$ 0.003  Millions
Repligen Corp  53.65 %$ 90.757  Millions$ 169.172  Millions
Adma Biologics Inc   53.55 %$ 61.097  Millions$ 114.097  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.